Coherus BioSciences Community
NasdaqGM:CHRS Community- 2 Narratives written by author
- 1 Comments on narratives written by author
- 21 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 3 Analysts
UDENYCA Divestiture And LOQTORZI Progress Will Forge Opportunity Amid Risks
Key Takeaways UDENYCA divestiture and headcount reduction will strengthen the balance sheet and improve margins through reduced expenses. Strategic expansions in oncology and new market opportunities aim to drive long-term revenue growth.
View narrativeUS$4.68
FV
80.1% undervalued intrinsic discount-26.55%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
7 days ago author updated this narrative